Featured

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced the appointment of Ajay Nirula, M.D., Ph.D., as the company’s executive vice president and head of research and development (R&D), and the addition of Adrian S. Ray, Ph.D., to its scientific advisory board (SAB).

Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson’s Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Capsida Biotherapeutics (“Capsida”), a leading fully integrated targeted gene therapy company, developing treatments for rare and common diseases across all ages, today announced eight presentations – three oral presentations and five poster presentations – at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD and virtually.

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

ACELYRIN, INC today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit – Improving Quality of Life for Patients

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS). These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.

Westlake-backed Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines

Westlake-backed Latigo Biotherapeutics, a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced its emergence from stealth with a $135 million Series A financing. Westlake Village BioPartners incubated the company. Westlake led the Series A financing with 5AM Ventures and Foresite Capital as co-leads with participation from Corner Ventures.